FUNDINNO PLus+ Secures 410 Million Yen for DFree Expansion Efforts

FUNDINNO Plus+ Secures 410 Million Yen for DFree Expansion Efforts

In a significant development for venture funding, FUNDINNO, based in Minato, Tokyo, has announced its successful capital raising of approximately 410 million yen for DFree Corporation. This was achieved through the FUNDINNO Plus+ program, which allows direct investments by specific investors, known as J-Ships. The service is designed to facilitate capital acquisition for unlisted companies by connecting them with professional investors.

A New Investment Opportunity

As a response to the overwhelming interest from investors, FUNDINNO will reintroduce investment opportunities starting from May 20, 2025, exclusively for those registered as specific investors. This initiative aims to leverage the enthusiasm and backing from various stakeholders in the healthcare and caregiving sectors, enabling further development and fruition of DFree's innovative solutions.

Notably, the special investor designation implies that participants must meet specific criteria demonstrating their professional investment capabilities. This ensures that the capital raised is managed responsibly by individuals sufficiently knowledgeable about financial products.

DFree's Mission and Product Offerings

DFree has developed the world's very first excretion prediction device named DFree, utilizing advanced ultrasound sensors to monitor bladder changes and predict the optimal timing for bathroom usage. This IoT wearable device aims to address the concerns surrounding bathroom needs, particularly for the elderly and individuals with mobility challenges.

DFree provides two distinct product lines: DFree Professional, targeted at care facilities and healthcare providers, and DFree Personal, designed for home use. The company is also expanding its operations internationally, gaining traction in the United States and Europe, aligning with its vision to harness technology to foster a society where everyone can live comfortably and confidently.

Executive Director Atsushi Nakanishi of DFree has emphasized the critical role of supportive investors in propelling the company towards greater heights. He believes the collaboration with individual investors who possess a long-term vision will complement DFree's rapid growth trajectory. Funds generated from this initiative will not only promote the expansion of existing services but will also facilitate the acquisition of necessary medical device certifications and support international ventures.

The Advantages of FUNDINNO Plus+

FUNDINNO Plus+ provides an exceptional platform for venture firms to secure substantial funding while enabling investors access to promising unlisted companies with growth potential. By participating as specific investors, capital providers can engage with businesses that are positioned near an Initial Public Offering (IPO), thus balancing risk with attractive returns.

FUNDINNO aims to democratize access within Japan's venture capital marketplace, ensuring opportunities for all entrepreneurs and investors to bridge information and opportunity gaps. The company’s mission is to empower entrepreneurs and connect aspiring investors with viable business opportunities, fostering a more inclusive and fair entrepreneurial environment.

FUNDINNO is dedicated to the continuous enhancement of its resources and offerings for both entrepreneurs seeking funding and investors searching for promising ventures. With offices in Tokyo and a robust operational framework, FUNDINNO is poised to remain at the forefront of Japan’s evolving investment landscape.

For more about FUNDINNO and their innovative funding options, please visit their official website at FUNDINNO.

Conclusion

This latest capital raise signals a growing trend of venture investment in Japan, highlighting opportunities for innovative companies like DFree. As Japan’s economy continues to recover, initiatives such as FUNDINNO Plus+ are pivotal for the growth of promising technologies aimed at enhancing quality of life, not only in Japan but worldwide as well. Investors are encouraged to take advantage of this unique opportunity to support a venture that is likely to create significant impacts in the healthcare sector.

For details regarding fees and risks associated with investments, please refer to the important disclosure documents available on the FUNDINNO website.